Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
Denmark
/
Pharmaceuticals & Biotech
Create a narrative
Gubra Community
CPSE:GUBRA Community
1
Narratives
written by author
0
Comments
on narratives written by author
2
Fair Values set
on narratives written by author
Create a narrative
Gubra
Popular
Undervalued
Overvalued
Community Investing Ideas
Gubra
AN
AnalystConsensusTarget
Consensus Narrative from 1 Analyst
AbbVie Agreement And Clinical Trials Will Unlock New Avenues
Key Takeaways Strategic partnerships and collaborations with top pharma companies ensure sustainable revenue streams and growth opportunities for Gubra. Promising clinical trial results and innovative treatments could boost future revenue and market position in weight management and obesity treatments.
View narrative
DKK 750.00
FV
46.3% undervalued
intrinsic discount
74.58%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
2 days ago
author updated this narrative
Your Valuation for
GUBRA
GUBRA
Gubra
Your Fair Value
DKK
Current Price
DKK 402.40
519.4% overvalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
-45m
466m
2015
2018
2021
2024
2025
2027
2030
Revenue DKK 465.7m
Earnings DKK 57.7m
Advanced
Set Fair Value